• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a delivery system comprising one or more nuclei and membranes. The nucleus and membrane are attached to the Si-atoms and / or poly (alkene oxide) groups of the siloxane units, for example in the form of alkoxy-terminated grafts or blocks, or mixtures thereof, connected to the polysiloxane units via silicon-carbon bonds. Siloxane-based elastomers comprising 3,3,3-trifluoropropyl groups; And elastomeric compositions comprising poly (dimethylsiloxane). This delivery system is preferably an insert or an intrauterine, cervical or intravaginal system.
    公开号:KR20040036928A
    申请号:KR10-2004-7003148
    申请日:2002-08-27
    公开日:2004-05-03
    发明作者:티모 하파쿰푸；쥬하 알라-소베리；마코 알토엔；앤티 케녀넨；맨자 아홀라
    申请人:쉐링 오와이；
    IPC主号:
    专利说明:

    Drug Delivery System {DRUG DELIVERY SYSTEM}
    [2] U.S. Pat.Nos. 6,056,976 and 6,299,027 and patent application 09 / 701,547, filed November 30, 2000 (the same WO 00/00550) are incorporated by reference.
    [3] Polysiloxanes, such as poly (dimethylsiloxane) (PDMS), are well suited for use as membranes or substrates that control the permeation of active agents within a variety of active agent forms, particularly implants and intrauterine-internal systems (IUS). Do. Polysiloxanes are physiologically inert and a wide range of active agents can penetrate the polysiloxane membrane. The membrane also has the required mechanical properties.
    [4] Applicant's pending 09 / 701,547 filed Nov. 30, 2000 exists as an alkoxy-terminated graft, or blocks, or mixture of these forms of polysiloxane units in an elastomer or polymer. Elastomer compositions comprising poly (alkene oxide) groups and poly (alkene oxide) groups are described. The block or graft is linked to the polysiloxane unit via a silicon-carbon bond. This application discloses a method of making such an elastomer.
    [5] The inventor's patented US Pat. No. 6,056,976 discloses that a 3,3,3-trifluoropropyl group is bonded to the Si-atom of the siloxane unit and the release rate of the therapeutically active agent of the delivery system is 3,3,3. Siloxane-based elastomers comprising 3,3,3-trifluoropropyl groups controlled by the capacity of trifluoropropyl groups are disclosed.
    [6] Some other publications describe delivery systems capable of releasing one or more therapeutically active agents. For example, US Pat. No. 5,972,372 describes a vaginal ring comprising a body having a first polymeric material and an interior passageway of a cavity. The ring further comprises a drug containing nucleus present in the inner passageway and made of a second polymerizable material. The polymerizable material may be, for example, a silicon elastomer such as PMDS or derivatives thereof containing fluoro-groups. However, this document does not disclose a nuclear-membrane structure.
    [7] U.S. Patent 5,443,461 discloses a diffusion delivery system. It consists of one or more compartments, each containing a therapeutically active agent. These active agents are released independently of each other. The wall segments between the compartments can be made of, for example, thermoplastic elastomers. This active agent is formulated in a composition comprising a diluent such as a polymer mixture. Polyethylene glycol mixtures are provided as examples of suitable mixtures.
    [8] U.S. Patent 5,496,557 provides a controlled delivery system of an active material comprising a cavity filled with the active material and enclosed by a wall. This wall is made of biodegradable polymer and provides only one filling example. The active substance is dispersed in so-called castor oil. This system therefore does not disclose nuclei made of elastomer. The system is further coated with a non-permeable biodegradable polymer and the diffusion rate of the active material is controlled by the surface of the wall not covered by the non-permeable polymer. The problem with this kind of system is that if this wall breaks down, the active substance is released out of control. Such release can cause serious problems either by side effects by the active substance or by poisoning by the active substance.
    [1] The present invention relates to a delivery system comprising a core and a membrane surrounding the core. Wherein said nucleus and membrane consist essentially of the same or different elastomer compositions.
    [153] La and lb show a first embodiment of the present invention.
    [154] 2 shows a second embodiment of the present invention.
    [155] 3 shows a third embodiment of the present invention.
    [156] 4 shows a fourth embodiment of the present invention.
    [157] 5 shows a fifth embodiment of the present invention.
    [158] 6 shows a sixth embodiment of the present invention.
    [159] 7 shows a seventh embodiment of the present invention.
    [160] 8 shows an eighth embodiment of the present invention.
    [161] 9 shows the results of Experimental Example 1. FIG.
    [162] 10 shows the results of Experimental Example 2. FIG.
    [163] 11 shows the results of Experimental Example 3. FIG.
    [164] 12, 13 and 14 show the results of Experimental Example 4. FIG.
    [9] It is an object of the present invention to provide a drug delivery system capable of releasing two or more different active agents simultaneously and at a constant, predetermined rate.
    [10] Another object of the present invention is to provide a delivery system that does not pose any risk to the subject to be administered even if the system is damaged.
    [11] It is also an object of the present invention to provide a delivery system that is easy to produce and cost-effective.
    [12] The invention is disclosed in the appended claims.
    [13] A nucleus and a membrane surrounding the nucleus, wherein the nucleus and the membrane consist essentially of the same or different elastomeric composition, wherein the system comprises two or more therapeutically active agents each having a different release rate in the nucleus. It is done.
    [14] These nuclei and membranes are made of an elastomeric composition that is substantially the same or different from that described below. In this application, the term "elastomeric composition" may mean one single elastomer or may refer to an elastomeric composition that may be made of two elastomers, one entangled on the other.
    [15] The elastomeric composition used in this membrane allows the active agent to have a predetermined, constant release rate. By selecting the elastomeric composition, the first object of the present invention can be achieved. Second, the nucleus consists of an elastomeric composition. In other words, the interior of the nucleus is an elastomeric matrix in which the active agent is dispersed. Therefore, even if the membrane surrounding the nucleus is damaged, the active agent is not released in an uncontrolled manner that can cause the problems described above to the subject. The elastomeric composition of this nucleus is chosen such that the rate of release from the nucleus of the active agent is faster than the rate of release through the membrane, but at a rate low enough to not cause problems. The release rate can be controlled by the membrane alone or by the nucleus and membrane. It is also possible to use the nucleus to primarily control the release rate, and the membrane to control the final release rate.
    [16] The delivery system according to the invention may be an implant, an intrauterine system, an intrauterine system or an intravaginal system. The manufacture of such systems is well known in the art but is described again below. The shape and size of this system can also be freely chosen by those skilled in the art. It is also clear that the system according to the invention can be applied to humans as well as animals. If this delivery system is for example an intrauterine system, it will further comprise a body forming the structure of the system. In this case, the nuclear-membrane structure of this system is hollowed out so that it can be located on the body of the system. This body may have a T, S or 7 shape.
    [17] According to a first embodiment of the invention, the nucleus consists of a portion comprising the two or more therapeutically active agents. According to another embodiment of the invention, the nucleus consists of at least two parts, each part consisting of two or more parts comprising at least one active agent of two therapeutically active agents. The elastomeric composition of the part is selected according to the release rate required and can be the same or different in each part. According to embodiments in which the nucleus consists of two or more parts, these parts may be located adjacent each other or in such a way that one part of the nucleus at least partially surrounds the other part. Any combination of structural elements is possible within the technical idea of the present invention. The advantage of using multiple parts is that there is no interaction between the actives, making it easier to control the release rate.
    [18] According to another embodiment of the present invention, the membrane consists of two or more layers each having a specific thickness. The thickness of these layers may be the same or different and the elastomer composition used in each layer may also be the same or different. The membranes that enclose each of the aforementioned portions of the nucleus may also have the same or different elastomeric composition or structure (single or multiple layers) of the membrane. The thickness or material of the membrane, or a combination of both layers, further enhances the controllability of the release rate of the active agent.
    [19] According to one embodiment, the system according to the invention further comprises a space separating two parts of said nucleus and / or at least one separation membrane separating two parts of said nucleus into two. The separator is composed of an elastomeric composition. It is also possible to produce a system according to the invention with a nucleus consisting of subdivisions of A, B and C, for example. Here, the parts A and B are separated by spaces, and the parts B and C are separated by membranes. Parts A and B are adjacent to each other without a film or space therebetween and parts B and C are separated by a film; A system and other combinations in which parts A and B are separated into a membrane composed of a first elastomer composition, and parts B and C are separated into a second elastomer composition different from the first elastomer composition are also within the scope of the technical idea of the present invention. Is in.
    [20] According to another embodiment of the present invention, the membrane is permeable or impermeable to one or more therapeutically active agents. It is also possible to use membranes which are permeable for the first active agent but impermeable to the second active agent.
    [21] According to one preferred embodiment of the invention, the elastomeric composition of the aforementioned elastomeric composition, the so-called nucleus, the membrane, and the separator, is the same or different and is selected from the group consisting of:
    [22] Elastomer compositions comprising poly (dimethylsiloxane),
    [23] An elastomer composition comprising a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units,
    [24] Elastomer composition comprising poly (alkene oxide) groups. The poly (alkene oxide) groups are bonded to the polysiloxane units by silicon-carbon bonds and exist as alkoxy-terminated grafts or blocks or as mixtures of these forms. And
    [25] Combinations of two or more thereof.
    [26] According to one embodiment of the invention, 1 to about 50% of the substituents attached to the Si-atoms of the siloxane units in the siloxane-based elastomer are 3,3,3-trifluoropropyl groups.
    [27] According to another embodiment of the present invention, the aforementioned poly (alkene oxide) group is a poly (ethylene oxide) group.
    [28] The elastomer composition described above is described in more detail.
    [29] According to another embodiment of the invention, the release rate of two or more therapeutically active agents may be the same or different. According to a preferred embodiment of the present invention, the therapeutically active agent is a hormone such as progestin, estrogen, anti-progesterone or androgen. The system also includes any other therapeutically active substance that is suitably associated with a given hormone or other active agent. Some examples of suitable therapeutically active agents are provided below.
    [30] According to one embodiment of the invention, the release rate of the therapeutically active agent in the intrauterine, cervical or intravaginal system is 0.1-300 μg / day. According to another embodiment of the invention, the release rate in the insert of the active agent was 0,1-300 μg / day, these examples being for hormones.
    [31] Combinations of the above embodiments are possible and are within the scope of the technical idea of the present invention. And those skilled in the art will find the most suitable combination for a particular use.
    [32] The manufacture of the system according to the invention is apparent to those skilled in the art. This system can be manufactured by extrusion or molding. This manufacturing method is described below.
    [33] Elastomer composition
    [34] One suitable elastomer for the use of the system according to the invention is a siloxane-base comprising a 3,3,3-trifluoropropyl group attached to the Si atom of the siloxane unit, in particular for use as a membrane. Elastomer.
    [35] The term “siloxane-based elastomer” should be understood to include elastomers made of poly (disubstituted siloxanes). Here, the substituents are mainly lower alkyl, preferably alkyl groups of 1 to 6 carbon atoms, or phenyl groups, wherein said alkyl or phenyl may be substituted or unsubstituted. A widely used and preferred type of polymer is poly (dimethylsiloxane) (PDMS).
    [36] According to the present invention, a certain amount of substituent attached to the Si-atom of the siloxane unit in the elastomer will be a 3,3,3trifluoropropyl group. Such elastomers can be obtained by other methods. According to one embodiment, the elastomer is applied to a single crosslinked siloxane-based polymer such as poly (dialkyl siloxane) in which a certain amount of alkyl groups in the Si-atom are replaced by 3,3,3-trifluoropropyl groups. Can be based. A preferred example of such a polymer is poly (3,3,3-trifluoropropyl methyl siloxane) and this structure is shown in compound I below.
    [37]
    [38] Compound I
    [39] Polymers of this kind (about 50% of methyl substituents at Si-atoms are replaced by 3,3,3-trifluoropropyl groups) are commercially available. The term "about 50%" means that the 3,3,3-trifluoropropyl substitution is less than about 50%. This is because the polymer must contain an amount of crosslinkable groups (about 0.15% of substituents) such as vinyl or vinyl-terminated groups. Similar polymers with a low degree of 3,3,3-trifluoropropyl substitution can be readily synthesized.
    [40] The delaying effect of 3,3,3-trifluoropropyl groups on the permeation of the active agent across the elastomeric membrane depends on the capacity of these groups. In addition, this delay effect depends significantly on the active agent used. If the elastomer is made of only a single polymer, it is necessary to make it using a polymer with different doses of 3,3,3-trifluoropropyl groups for different actives.
    [41] According to another embodiment, particularly preferably, if a suitable elastomer is required for the different actives, a) a non-fluoro substituted siloxane-based polymer and b) a fluoro substituted siloxane-based polymer The mixture is crosslinked. Wherein the polymer comprises a 3,3,3-trifluoropropyl group attached to the Si-atom of the siloxane unit. The non-fluoro substituted polymer, which is the first component of the mixture, may be any poly (disubstituted siloxane), wherein the substituents are mainly lower alkyl, preferably alkyl groups of 1 to 6 carbon atoms, or phenyl groups, where The alkyl or phenyl may be substituted or unsubstituted. The substituent is most preferably an alkyl group of 1 to 6 carbon atoms. Preferred non-fluorosubstituted polymers are PDMS. The fluoro-substituted polymer of the second component of the mixture can be, for example, a poly (dialkyl siloxane) in which a certain amount of alkyl group in the Si-atom is substituted with 3,3,3-trifluoropropyl group. Preferred examples of such polymers are poly (3,3,3-trifluoropropyl methyl siloxane) as described above. Particularly preferred polymers of this kind are polymers having as high a capacity as possible of 3,3,3-trifluoropropyl substituents, with about 50% of the methyl substituents at Si-atoms being 3,3,3-trifluoropropyl groups Commercially available polymers replaced with. Elastomers with a significant delay in administration can be obtained by using the polymers described above primarily or alone. Elastomers with less retarding effect on the permeation of the active agent can be obtained by using mixtures with increased capacity of non-fluorosubstituted siloxane base polymers.
    [42] Other elastomers used in the present invention include poly (alkene oxide) groups in which the poly (alkene oxide) group is present in the elastomer as an alkoxy-terminated graft or block of polysiloxane units, and the graft or block Is linked to the polysiloxane unit via a silicon-carbon bond. Poly (alkylene oxide) may also be present as optional mixtures described above. The second elastomer may be a siloxane base elastomer, suitably a poly (dimethyl siloxane) -based elastomer. The second elastomer may also include a poly (alkene oxide) group. These poly (alkene oxide) groups may also exist as alkoxy terminated grafts or blocks of poly (dimethyl siloxane) units, which grafts or blocks are linked via silicon-carbon bonds to the poly (dimethyl siloxane) units. . Poly (alkylene oxide) may also be present in this elastomer as the optional mixtures described above.
    [43] According to one embodiment of the invention, the elastomer composition comprises a siloxane-based elastomer, made of one or more straight-chain polysiloxane copolymers comprising, for example, PDMS and poly (alkene oxide) groups. It may be a mixture. In this case the poly (alkene oxide) group is present in the polymer as an alkoxy terminated graft or block of polysiloxane units, which graft or block is linked to the polysiloxane unit by silicon-carbon bonds. This poly (alkene oxide) group can, of course, also be present as a mixture of the aforementioned form in the polymer. In this embodiment, the siloxane-based elastomers may also comprise poly (alkene oxide) groups, in which case these poly (alkene oxide) groups are present as alkoxy terminated grafts or blocks of polysiloxane units in the elastomer. The block or graft is connected to the polysiloxane unit via a silicon-carbon bond. These poly (alkene oxide) groups may also be present as mixtures of the aforementioned forms.
    [44] Of course, this elastomer composition may also be made of two elastomers, one entangled on the other and one or more straight chain polysiloxane copolymers comprising poly (alkene oxide) groups as above.
    [45] The poly (alkene oxide) group of this elastomer composition is suitably, for example, a poly (ethylene oxide) group (PEO group).
    [46] The polysiloxane unit of this elastomer composition is preferably a group having the formula
    [47] -(SiR'R "O) q SiR'R"-
    [48] Wherein R ′ and R ″ are the same or different and are partially free groups which are lower alkyl groups, or phenyl groups, in which case the alkyl or phenyl groups are substituted or unsubstituted, or an alkoxy-terminated poly having the formula Alkene oxide) group,
    [49]
    [50] Where alk is a lower alkyl group, suitably methyl, R is hydrogen or lower alkyl, m is 1 ... 30, and R 3 is a straight or branched C 2 -C 6 alkyl group,
    [51] Forming a bond formed from hydrogen or an alkylene group in part to another polymer chain in the elastomer, and
    [52] A partially unreacted group such as hydrogen, vinyl or vinyl terminated alkenes, and
    [53] q is 1 ... 3000.
    [54] The term "lower alkyl" generally means a C 1 -C 6 alkyl group here and in the context of the present invention.
    [55] The aforementioned free groups R 'and R "groups are suitably lower alkyl groups, preferably methyl.
    [56] The term "poly (alkene oxide) group" means a group comprising two or more alkyl ether groups connected in series with one another.
    [57] According to a preferred embodiment, the poly (alkene oxide) group is present in the form of a poly (alkene oxide) block having the formula below the elastomer.
    [58]
    [59] Wherein R is hydrogen, lower alkyl or phenyl, R 1 is hydrogen or lower alkyl, y is 2 ... 6, and m is 1 ... 30.
    [60] Preferred combinations of elastomers are PDMS and poly (ethylene oxide) PDMS and PDMS with fluorosubstituted PDMS.
    [61] The elastomer preferably comprises a filler, such as amorphous silica, to provide sufficient strength to the film made from the elastomer. The polymer may further include other additives, which should be biocompatible and harmless to the subject to be administered.
    [62] Methods for preparing these elastomers are provided in the above-described patents and patent applications of the applicant.
    [63] Examples of suitable materials include polyethylene, polypropylene, polymethylpentene ethylene / propylene copolymers, ethylene / ethyl acrylate copolymers, ethylene / vinyl acetate copolymers, polycarbonates, polytetrafluoroethylene (PTFE), fluoroethylene Propylene (FEP) @ Polyvinylidene Fluoride (PVDF), Polyvinylacetate, Polystyrene, Polyamide, Polyurethane, Polybutadiene, Polyisoprene, Chlorinated Polyethylene, Polyvinyl Chloride, Vinyl Chloride Copolymer and Vinyl Acetate, Poly (Methacrylate), polymethyl (meth) acrylate, poly (vinylidene) chloride, poly (vinylidene) ethylene, poly (vinylidene) propylene, polyethylene tetraphthalate, ethylene vinyl acetate, polyhydroxy alkanate poly ( Lactic acid), poly (glycolic acid), poly (alkyl 2) -Cyanoacrylate), polyanhydrides, polyorthoesters, ethylene / vinyl alcohol copolymers, ethylene / vinyl acetate / vinyl alcohol trimers; Hydrophilic polymers such as ethylene / vinyloxyethanol copolymers, ethylene / vinyl / acetate copolymers, ethylene vinyl / alcohol copolymers, esters of acrylic and methacrylic acids, modified collagen, crosslinked polyvinyl alcohol, crosslinked And the presence of partially hydrolyzed polyvinyl acetates, silicon elastomers, especially medical grade polydimethyl siloxanes, polyvinylmethylsiloxanes, other organopolysiloxanes, polysiloxanes, neoprene rubbers, butyl rubbers, epichlorhydrin rubbers, curing catalysts at room temperature Room temperature vulcanizing type hydroxyl-terminated organopolysiloxanes which cure the elastomer upon addition of a crosslinking agent, a two-component dimethylpolysiloxane composition capable of intercalating platinum catalyzed and crosslinking at room temperature or elevated temperature and these It contains a mixture of.
    [64] Preparation of Inserts
    [65] Inserts of the invention can be prepared according to standard techniques. The therapeutically active agent is mixed with the nuclear matrix elastomer composition and processed into the desired form using a mold, casting, extrusion, or other suitable method. The membrane layer can be subjected to known methods such as mechanical stretching, swelling or dipping on the nucleus. See US patents US 3,832,252, US 3,854,480 and US 4,957,119. Suitable methods for the preparation of inserts are disclosed in Finnish patent FI 97947. This patent describes an extrusion technique, which is a technique of coating a prefabricated rod containing an active ingredient with an outer membrane. Each such rod is accompanied by another rod, for example without any active ingredient. The formed thread is cut in a rod that does not contain an active agent. In this way, it is not necessary to specifically seal the end of the insert.
    [66] Manufacture of intrauterine, intravaginal and cervical systems
    [67] Intrauterine systems can be prepared by known techniques. A preferred intrauterine system (IUS), intravaginal system or cervical system commonly used is a T-shaped body made of a plastic material such as polyethene. The body consists of an elongate member having a transverse section comprising two wings at one end. The elongate section and the transverse section form a substantially T-shaped section when the system is located in the uterus. The system has an attached thread that is long enough to exit the cervical catheter when placed in the uterus. The system may also have other forms such as 7, S, omega, ring or C-type. The IUS: s releasing active agent has an active agent reservoir (corresponding to the nucleus or nuclear-membrane herein) around the extension. It is also possible to have one repository in one part of the IUS and another repository in another part of the IUS. This activator reservoir becomes the delivery system according to the invention, ie the nucleus surrounded by the membrane. Intrauterine, intravaginal and cervical systems according to the invention also include a body, to which a system comprising the nucleus and membrane is attached.
    [68] T-shaped intrauterine systems typically first separate the body and the reservoir and then pull the reservoir over the body and then position it to form a membrane over the reservoir, thus forming a core-membrane structure.
    [69] Therapeutic actives
    [70] Representative examples of therapeutically active agents suitable for the present invention include the following. (Bundled according to therapeutic classification).
    [71] Hydralazine, minoxidil, captopril, enalapril, clonidine, prazosin, debrisoquine, diazoxide, guanethidine, Antihypertensive agents such as methyldopa, resulfin, trimethaphan, nifedipine and isradipine;
    [72] Calcium channel blockers such as diltiazem, felodipine, amlodipine, amlodipine, nitrendipine, nifedipine and verapamil;
    [73] Arnidarone, flecainide, disopyramide, procaineamide, mexiletene quinidine, lorcainide and beprie Antiarrhyrthmics such as bepridil;
    [74] Glyceryl trinitrate, erythyl tetranitrate, pentaerythritol tetranitrate, mannitol hexanitrate, perhexilene, isosorbide dinitrate nicorandil and Nicardipine and anti-angina agents;
    [75] Alprenolol, atenolol, atenolol, bupranolol, carteolol, labelolol, labetalol, metoprolol, nadolol, nadoxolol, ox Oxprenolol, pindolol, propranolol, propanolol, sotalol, timolol timolol maleate, bisprolol, bisprolol, celiprolol and Β-adrenergic blockers such as betaxolol;
    [76] Cardiac glycosides such as digoxin and other cardiovascular glycosides and theophylline derivatives;
    [77] Adrenaline, ephedrine, fenoterol, isoprenaline, isoprenaline, orciprenaline, remeterol, salbutamol, salmeterol Adrenergic stimulants, such as terbutaline, dobutamine, dobutamine, phenylephrine, phenylpropranolamin, pseudoephedrine and dopamine;
    [78] Cyclandelate, isoxsuprine, papaverine, dipyridamole, isosorbide, dinitrate, phentolamine, nicotyl alcohol, co- Vasodilators such as co-dergocrine, nicotinic acid, glyceryl trinitrate, pentaerythritol tetranitrate zanitol, vincamine and nimodipine;
    [79] Migraine such as ergotamine, dihydroergotamine, metysergide, pizotifen sumatriptan, and flumendroxon;
    [80] Anti-blood coagulants such as warfarin, ticlopidine, iloprost, dicoumarol, enoxaparin, low molecular weight heparin and streptokinase and its active derivatives ( Anticoagulants and thrombolytic agents;
    [81] Hemostatic agents such as aprotinin, tranexamic acid, and protamine;
    [82] Buprenorphine, dextromoramide, dextropropoxyphene, pentanyl, fentanyl, alfentanil, sulfentanyl, hydromorphone, methadone ), Morphine, oxycodone, papaveretum, pentazocine, petidine, phenoperidine, codeine, codeine, dihydrocodeine, Narcotic analgesics such as sufentanil and tilidine and flufenamic acid, indomethacin, ibuprofen, ketoprofen, tramadol, Analgesics and antipyretics, including non-narcotic analgesics such as diflunisal, rimazolium, acetylsalicylic acid, paracetamol and phenazone antipyretics);
    [83] Neurotoxins such as capsaicin;
    [84] For example, neuroleptics such as butyrophenone derivatives such as haloperidol, or bacteriostatics and / or fungistats such as nystatin or metronidazole;
    [85] Sleeping and sedatives such as barbiturates amylobarbitone, butobarbitone and pentobarbitone and chloral hydrate, chlormethiazole, hydroxyzine and Other hypnotics and sedatives, such as meprobarnate;
    [86] Benzodiazepines alprazolam, bromazepam, clodiazepoxide, clobazam, chlorazepate, diazepam, flunitrazeparn, flunirazeparn Anti-anxiety agents such as flurazepam, lorazepam, nitrazepam, nitrazepain, oxazepain, ternazepam triazolam and buspirone;
    [87] Phenothiazines, chlorpromazine, fluphenazine, pericyazine, perphenazine, promazine, thiopropazate, Neuroleptic and antipsychotic drugs such as thiolidazine, trifluoperazine; And butyrophenone, droperidol and haloperidol; And other antipsychotics such as pimozide, thiothixene;
    [88] Bicyclic derivatives such as nomifensine, sertraline and trazodone, amitryptyline, clomipramine, desipramine, and dotipin Tricyclic anti-depressants such as doxepin, imipramine, nortriptyline, oppiprainol, protriptyline and trimipramine , Tetracyclic anti-depressants such as mianserin, and monoamines such as isocarboxazid, phenelizine, trany1cypromine and moclobemide Oxidase inhibitors and selective serotonin reuptake inhibitors such as fluoxetine, paroxetine, citaloprain, fluvoxamine and sertraline Anti-depressants (Antidepressants);
    [89] CNS stimulants such as caffeine, methylphenidate, nizophenone and 3- (2aminobutyl) indole;
    [90] Anti-alzheimer's agents such as tacrine, physostigmine and olanzapine;
    [91] Amantadine, benzrazide, carbidopa, levodopa, benztropine, biperiden, benzhexol, benzhexol, procyclidine ), Anti-Parkinson's such as seleginyl, entacapone, and dopamine-2 antidote, such as S (+ 2- (N-propyl-N thienylethylamino) hydroxytetraline;
    [92] Phenytoin, valproic acid, primidone, phenobarbitone, phenobarbitone, methylphenobarbitone and carbamazepine, ethosuximide, mesuccimid ( anti-convulsants such as methsuximide, phensuximide, sulthiame and clonazepam;
    [93] Phenothiazines prochloperazine, antiemetics and antinauses such as cyethylperazine and dimenhydrinate, diphenhydramine, methotlopramide ( metoclopramide, domperidone, hiyosine, hyoscine hydrobromide, hiyocin hydrolon chloride, clebopride and bromprid, as well as ondansetron and granny 5HT-3 receptor antagonists such as granisetron;
    [94] Ibuprofen, flurbiprofen, ketoprofen, aceclofenac, diclofenac, dilofenac, aloxiprin, aproxen, aspirin, difluni Diflunisal, fenoprofen, indomethacin, mefenamic acid, naproxen, phenylbutazone, piroxicam, salicylamide, Salicylic acid, sulindac, desoxysulindac, tenoxicam, tramadol, ketoralac, flufenisal, salsalate ), Triethanolamine salicylate, aminopyrine, antipyrine, oxyphenbutazone, apazone, citazone, flufenamic acid ( flufenamic acid, clonixeril, clonixin, meclofenamic Acid (meclofenamic acid), flunixin, coichicine, demecolcine, allopurinol, oxypurinol, benzydamine hydrochloride, dimefedane, phosphorus Indoxo1e, intrazole, ambane hydrochloride, paraylene hydrochloride, tetridamine, benziphyrin hydrochloride, fluprofen, ibufenac , Naproxol, fenbufen, fenchofen, diflumidone sodium, fenamole, flutiazin, metazamide, reti Amide hydrochloride, Nexeridine hydrochloride, octazamide, molinazole, neoocinchophen, nimazole, proxazole citrate, tesicam , Tesimide, tall Anti-inflammatory agents such as tommetin, carprofen, mesalazine and triflumidate, including their racemic mixtures or individual enantiomers, preferably in use Anti-inflammatory agents that can be formulated with penetration enhancers. ;
    [95] Antirheumatoid agents such as penicillamine, aurothioglucose, sodium aurothiomalate, merotrexate and orranofin;
    [96] Muscle relaxants such as baclofen, diazepam, cyclobenzaprine hydrochloride, dantrolene, metocarbamol, orphenadrine and quinine );
    [97] Agents used for gout and hyperuricaernia such as allopurinol, colchicine, probenecid and sulfinpyrazone;
    [98] 3-methoxy-17α-ethynyll-1,3,5 (10) -estratrien-17-ol (methranol), 3-hydroxy-1,3,5 (10) -estritriene -17-one (estrone), 17β-estradiol, estriol, ethynylestradiol, 4-pregnene-3,20-dione (progesterone), d-13-ethyl17α-ethynyl hydroxy-4- Gonen-3-one (d-norgestrel) and their esters, 17α-ethynyl-19-nortestosterone (norethosterone) and their esters, 6-chloro-17-hydroxy-lα, 2α-methyleneph REGNA-4,6-diene-3,20-dione (cyproterone) and their esters, 19-norhydroxyprogesterone and their esters, 6-chloro-17-acetoxy-pregna-4,6-diene- 3,20-dione (chlorminone acetate), 15,16α-methylene- and 15,16β-methylene-17βhydroxy-18-methyl-17α-ethynyl-4-destre-3-one, 17α-ace Methoxy-6αmethylprogesterone (medoxy-progesterone acetate), 9β, 1 0α-pregna-4,6-diene-3,20-dione (didrogesterone), estradiol-3-methyl ether diethylstilbestrol, 17α-ethynyl estrene-3β, 17β-diol diacetate, 17α-ethynel-11β-methyl-4 estrene 3β, 17β-diol 3,17-diacetate, 17α-acetoxy-llβ-methyl-19-norpreg-4-en-3-one, testosterone , Testosterone propione, testosterone phenylacetate and related androgens, allloestrenol, lynoestrenol, norgestrel, norethyndrel, norethisterone ), Noreosterone acetate, gestodene, levonorgestrel, medroxyprogesterone, megestrol, testosterone, methyltestosterone, clostebol acetate, drostanolone ( drostanolone), furazabol, nandrolone oxane Drolone (oxandrolone), stanozolol, trobolone acetate, dihydro-testosterone, 17-α-methyl nortestosterone, norethindrone, etonogestrel, desogestrel hormones such as desogestrel and fluoxymesterone;
    [99] Corticosteroids such as desoxyoxycorticosterone acetate, prednisolone;
    [100] Anti-androgens such as cyproterone acetate, flutamide, nilutamide and damazol;
    [101] Antiestrogens such as tamoxifen, tolemifene, clomifene and epitiostanol;
    [102] Aromatase inhibitors such as letrozole, exemestane and 4-hydroxy androstenedione and derivatives thereof;
    [103] 5-α reductase inhibitors such as finasteride and turosteride;
    [104] Betamethasone, betamethasone balerate, cortisone, dexamethasone, dexamethasone 21-phosphate, flufacocortisone, flumethasone, flucyionide, flusonide desonide, flucinolone, flucinolone acetonide, flucortolone, hacinono Nitrate, halopredone, hydrocortisone, hydrocortisone 17-valorate, hydrocortisone 17-butyrate, hydrocortisone 21-acetate, methylprednisolone, prednisolone, prednisolone 21-phosphate, prednisolone, triamcinolone, triamcinolone acetosteroid, such as cortisonide;
    [105] Cortodoxone, plefolol acetonide, plefocorcortone, difluorson diacetate, flulandrenolone acetonide, medridone, amcinofel, amcinofade, betamethasone and its other esters, chloroprednisone , Chlorcortelone, decinolone, desonide, dichlorisone, difluprednate, flucloronide, flumetason, flunisolide flunisolide, flucortolone, fluorometallon, fluperolone, fluprednisolone, meprednison, methylmeprednisolone, paramethasone, cortisone acetate, hydrocortisone cyclopentylpropionide, cortodoxone ), Flucetonide, flufacocortisone acetate, fluandrenolone acetonide, medridone, child Trumpet (aincinafal), amcinofade, betamethasone, betamethasone benzoate, chloroprednisone acetate, clocortolone acetate, decinolone acetonide, desoxymethasone, dichlorison acetate, difluprenate, flucloronide ), Flumetason pivalate, flunisolide acetate, fluperolone acetate, fluprednisolone valerate, paramethasone acetate, prednisolamate, prednival, triamcinolone hexacetonide, cortivazol ), Steroidal anti-inflammatory agents such as formocortal and nivazol;
    [106] Pituitary hormones and their active derivatives or analogues, such as corticotrophin, thyrotropin, follicle stimulating hormone, luteinizing hormone and gonadotropin releasing hormone;
    [107] Insulin, chlorpropamide, clibenclamide, gliclazide, gliclazide, glipizide, tolazamide, tolbutamide and metformin Hypoglycemic agents such as;
    [108] Thyroid hormones such as calcitonin, thyroxine and liothyronine and anti-thyroid agents such as carbimazole and propylthiouracil;
    [109] Other hormones such as octreotide;
    [110] Pituitary inhibitors such as bromocriptine;
    [111] Ovulation inducing agents such as cloniniphene;
    [112] Diuretics such as thiazides, related diuretics, and loop diuretics, bendroflumethiazide, chlorocyzide, chlorthalidone, dopamine, cyclopen Cyclopenthiazide, hydrochlorocyanide, indapamide, mefruside, methichlorthiazide, metolazone, quinetazone, boonethazone, minor Bumetanide, ethacrynic acid and prosemide and potassium deficient diuretics, spironolactone, amylolide and triamterene;
    [113] Antidiuretics such as demospressin, lypressin and vasopressin, active derivatives or analogs thereof;
    [114] Gynecological drugs including agents acting on the uterus such as ergometrine, oxytocin and gemeprost;
    [115] Prostaglandins such as alprostadil, prostacyclin, dinoprost (prostaglandin F2alpha) and misoprostol;
    [116] Antibacterial agents including cephalosporins such as cephalexin, cefoxytin and cephalothin;
    [117] Amoxicillin, Amoxicillin and Clavulanic Acid, Ampicillin, Bacampicillin, Benzatin Penicillin, Benzalpenicillin, Carbenicillin, Kloxacillin, Methicillin, Peneticillin, Phenoxymethylphenicillin, Flucloxacillin, Mezziocillin Penicillins, such as piperacillin, ticarcillin and azocillin;
    [118] Tetracyclines and other tetracycline-type antibiotics such as minocycline, chlortetracycline, tetracycline, demeclocycline, doxycycline, metacycline and oxytetracycline;
    [119] Aminoglycosides such as amikacin, gentamicin, kanamycin, neomycin, netylmicin and tobramycin;
    [120] Amorolpin, Isoconazole, Clotrimazole, Econazole, Myconazole, Nystatin, Terrubinapine, Biponazole, Amphotericin, Glycopulbine, Ketoconazole, Fluconazole and Flucytocin, Salicylic acid, Pezathion Antifungal agents, such as titlaton, tolnaftate, triacetin, zinc, pyrithione, and sodium pyrithione;
    [121] Quinolones such as nalidixic acid, cinoxacin, ciprofloxacin, enoxacin and norfloxacin;
    [122] Sulfonamides such as phthalyl sulfthiazol, sulfadoxin, sulfadiazine, sulfamethiazole and sulfamemethazole;
    [123] Sulfones such as dapson;
    [124] Chloramphenicol, clindamycin, erythromycin, erythromycin ethyl carbonate, erythromycin estoleate, erythromycin ethyl succinate, erythromycin ethyl succinate, erythromycin lactobionate, roxysomycin, rinomycin, natamycin, nitrofucin , Spectinomycin, vancomycin, actreonine, colistin IV, metronidazole, tinidazole, pushdick acid, trimetapririm, and 2-thiopyridine N-oxide; Halogen compounds, especially iodide-PVP complexes and diiodohydroxyquines, hexachloropheniodes and iodine compounds; Chlorhexidine; Chloramine compounds; And other antibiotics such as benzoyl peroxide;
    [125] Anti-tuberculosis drugs such as etambutol, isoniazid, pyrazineamide, rifampicin and clofazimin;
    [126] Antimalarial agents such as primaquine, pyrimethamine, chlorquine, hydrocyclochlorquine, quinine, mefloquine and halopantrin;
    [127] Antiviral agents such as acyclovir and acyclovir prodrugs, famciclovir, zidovudine, didanosine, stavudine, lamivudine, zalcimin, squinaver, indinavir, ritonavir, n-docosanol, tromantadine and idocuridine;
    [128] Insect repellents such as mebendazole, thibendazole, niclosamide, praziquantel, pyrantel embonate and diethylcarbazine;
    [129] Plicainycin, cyclophosphamide, dacarbazine, fluorouracil and prodrugs thereof, methotrexate, procarbazine, 6-mercaptopurine and mucophenolic acid Cytotoxic agents such as;
    [130] Appetite loss and weight loss agents including dexfenfluramine, fenfluramine, diethylpropion, marginol, and phentermine;
    [131] Agents used for hypercalcemia, such as caltriol, dihydrotachisterol and their active derivatives and analogs;
    [132] Antitussives such as ethyl morphine, dextrometophan and polcodine;
    [133] Expectorants such as carbolcysteine, bromhexine, emethine, quanifesin, ipecacuanha and saponins;
    [134] Decongestants, such as phenylephrine, phenylpropanolanin and sudoethedrin;
    [135] Such as ephedrine, phenoterol, olifrenulin, limitrol, salbutamol, sodium crocoglycate, chromoglycic acid and its prodrugs, tubutalin, ipratopium burmide, salmeterol and theophylline and theophylline derivatives Bronchodilators;
    [136] Meclozin, cycline, chlorcycline, hydroxyzin, brompheniramine, chlorpheniramine, clemastine, cycloheptadine, dexchlorpheniramine, diphenhydramine, diphenylamine, doxylamine, mebrohydroline, peniramine Antihistamines, such as prepolydine, azatadine, diphenylpyraline, methadillazine, tufenadin, asternizol, loratidine, acribastin, cinarizine and cetirizine;
    [137] Such as bupivacaine, ametocaine, lignocaine, lidocaine, chincocaine, dibucaine, mepivacaine, prilocaine, ethidocaine, veratridine (c-fiber blocker specificity) and procaine Local anesthetics;
    [138] Stratum corneum lipids such as ceramides, cholesterol and free fatty acids for improving skin barrier repair;
    [139] Neuromuscular blocking agents such as susamethonium, alcuronium, pancuronium, atracurium, galamine, tubocacurin and becuronium;
    [140] Smoking cessation agents such as nicotine, bupropion and ibogaine;
    [141] Dermatological preparations such as vitamins A, C, B 1 , B 2 , B 6 , B 12a and E, vitamin E acetate and vitamin E sorbate, vitamin K;
    [142] Allergens for desensitisation, such as house, dust, mite antigens;
    [143] Nutrients such as vitamins, essential amino acids and fats;
    [144] Keratolytic agents such as alpha-hydroxy acid, glycolic acid and salicylic acid;
    [145] Metromidazoles, such as metronidazole, antiprotozoal agents;
    [146] Drug antagonists and agents such as naltrexone, naloxone, cyclazosine, metazosin, morphine, oxymolphone, methadone, fentanyl, serpentanyl, alfentanil, buprenoline, pentazocin and nalopine;
    [147] Alendronate, Shimadronate. Chloronate, Itidronate, Ibandroneti, Nerindronate, Olpadronate, Pamidronate, Risedroneide, Tiludronate, Icadronate, [1-hydroxy (1-pyrroli) Biforces such as diyl) -propylidene] bisphosphonate, [1-hydroxy imidazo- (1,2-a) diridine-3-ylethylidene] bis-phosphonate and zoleronate Bone activators including phonates;
    [148] Compounds having anti-progesterone properties, for example as disclosed in WO 01/47490;
    [149] Antihyperlipernic agents such as bezafibrate, fenofibrate, clotipol and statins.
    [150] Other pharmacologically active agents are anti-bacterial agents, anti-diabetic agents, anti-embolism agents, anti-muscarinic agents, anti-tumor agents, erectile dysfunction agents, immunosuppressants, antiprotozoal agents, β-blockers, anti-Parkinson's disease agents , Gastrointestinal agents, lipid modulators, cox-2-inhibitors, leukotriene inhibitors, macrolides, protease inhibitors, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-incontinence agents, anti-positive Prostatic hypertrophy, thrombin inhibitors, antithrombinogens, thrombolytics, fibrin solubilizers, vascular potentiators, calcium channel blockers, surface glycoprotein receptor inhibitors, antiplatelet agents, antimitotic agents, microtubule inhibitors, antisecretory agents, actin Inhibitors, remodeling inhibitors, antisense nucleotides, antimetabolic agents, antiproliferative agents, anticancer chemotherapy agents, growth hormone antagonists, growth factors, radiotherapy, peptides, proteins, enzymes, extracellular matrix components, free Radical scavengers, chelators, antioxidants, antipolymerases, photodynamic therapies, gene therapies, pharmacologic drugs, drugs for the central nervous system, drugs for the autonomic nervous system, autonomic ganglion blockers, for peripheral nervous system Drugs, ophthalmic drugs, drugs for sensory organs, heart disease, diuretics, vascular enhancers, vasoconstrictors, anti-arteriosclerosis, circulatory drugs, respiratory stimulants, drugs for respiratory organs, gastric ulcer drugs, gastric digestive agents, antacids, laxatives, Biliary, digestive, urethral preservatives, genitourinary drugs, anal diseases, nutritional tonics, drugs for blood or body fluids, liver disease drugs, antidote agents, addictive drugs, antigout agents, enzyme preparations, cell activation drugs, antitumor Agents, α-adrenergic blockers, cholinesterase inhibitors, anti-angiogenic factors, anti-arthritis agents, anti-diarrhea agents, anti-leukemic drugs, anti-aids drugs, dementia Drugs, angiotensin inhibitors, α- and β-agonists, wound-treatment enhancers, calcium antagonists, pancreatic hormones, antispasmodics, cardiovascular agents, muscle contractors, gonadotropins, heart failure agents, antifungal agents, neurotrophic factors, proton pump inhibitors, Antipruritic agents, anti-addictive drugs, histamine-receptor antagonists, immunosuppressants and immunostimulants.
    [151] In this specification, the terms "comprises" and "comprising" include "includes", "includes" and "including", except where the content needs to be interpreted differently. That is, when the invention is described as including specific features, various embodiments of the same invention also include additional features, and the referenced symbols are to be construed as limiting the claims. Can not be done.
    [152] The invention is explained in more detail by the following non-limiting figures and experimental examples.
    [165] La and lb show a first embodiment of the present invention. In figure la, insert 1 according to the invention is shown. Lb shows the same insert in more detail. This insert is surrounded by a membrane whose nucleus consists of two parts (3, 4), each containing a different therapeutically active agent. The other separator 5 separates the two parts 3 and 4.
    [166] 2 shows a second embodiment of the present invention. This system represents an insert or part of an intrauterine, cervical or intravaginal system. It consists of a nucleus comprising two parts 6, 7, each containing a therapeutically active agent. In this embodiment, there is no membrane between the two parts (as in 8 of FIG. 2), but the elastomer composition used in the two parts is different. The nucleus is surrounded by a membrane composed of two different elastomers 9, 10.
    [167] 3 shows a third embodiment of the present invention. The system comprises three parts (11, 12, 13), separated by membranes 14 and 15, which are permeable to the active agent contained in part 11 and not active in the active agent contained in part 12. It is permeable and the separator 15 is impermeable to the active agent contained in the portions 12 and 13. Part 13 contains two different active agents. The system is further surrounded by a membrane consisting of three parts 16, 17 and 18.
    [168] 4 shows a fourth embodiment of the present invention. The system consists of a nucleus 20 comprising three active agents and is further surrounded by a first membrane 19 and a second membrane 20 thicker than the first membrane.
    [169] 5 shows a fifth embodiment of the present invention. The nucleus of this system consists of three parts 22, 23 and 24. The portion 23 partially surrounds the portion 22 and surrounds both the portions 22 and 23 of the portion 24. The parts 22, 23 are separated by the separator 27, the parts 23, 24 are separated by the separator 26, and the parts 22, 24 are separated by the separator 25. The nucleus is then surrounded by a first membrane 28, a second membrane 29, and a third membrane 30. The third film is thicker than the first and second films. The distance between the membranes is shown enlarged for clarity.
    [170] 6 shows a sixth embodiment of the present invention. This system is an intrauterine system that includes a T-shaped body 35. The nucleus consists of four parts (31, 32, 33, 34). Each nucleus is surrounded by a membrane. The portions 31, 32 of the nucleus are separated from each other and separated by space from the portion 33. Portions 33 and 34 are adjacently separated by a separator 36.
    [171] 7 shows a seventh embodiment of the present invention. The system is a vaginal inner ring, consisting of a first portion 40 of the nucleus surrounded by a second portion 41 of the nucleus. The portions are separated by a separator 38 and the inner surface of the portion 40 and the outer surface of the portion 41 are surrounded by the membranes 37, 39, respectively.
    [172] 8 shows an eighth embodiment of the present invention. The nucleus of this system includes two parts 42, 43 separated by space 44.
    [173] Experiment
    [174] The present invention is described in more detail by the following experimental examples but not limited thereto.
    [175] Experimental Example 1
    [176] Inserts were prepared comprising levonorgestrel with a target release rate of 50 μg / day and estradiol with a target release rate of 10 μg / day.
    [177] This insert structure was that shown in FIG. The first part of the nucleus consisted of PDMS containing levonorgestrel and was 35 mm long. The second part of the nucleus consisted of PEO-PDMS with 50% PEO, contained estradiol and was 8 mm long.
    [178] The nuclear portion was surrounded by a membrane consisting of 10:90 ratio of PEO-PDMS. The thickness of the membrane was 0.2 mm and the outer diameter of the insert was 2.48 mm.
    [179] The measured release rate is shown in FIG. 9. The square in the figure is the release rate of estradiol, and the rhombus represents the release rate of levonorgestrel. It can be seen that the target release rate of estradiol was achieved, and the release rate of levonorgestrel was 60-40 μg / day instead of the target 50 μg / day.
    [180] Experimental Example 2
    [181] 11- (4-acetylphenyl) -17-hydroxy-17- (1,1,2,2,2-pentafluoroethyl), wherein the insert according to Experimental Example 1 had a target release rate of 50 μg / day as the active agent. It was prepared using estra-4,9-dien-3-one (antiprogesterone) and estradiol with a target release rate of 10 μg / day.
    [182] The insert structure was that disclosed in FIG. The first part of the nucleus consisted of 50:50 ratio PEO-PDMS containing Compound 1 and was 34 mm long. The second part of the nucleus consisted of PEO-PDMS with 50% PEO, contained estradiol and was 6 mm long.
    [183] The nuclear portion was surrounded by a membrane consisting of 20:80 ratio of PEO-PDMS. The thickness of the membrane was 0.2 mm and the outer diameter of the insert was 2.48 mm.
    [184] The measured release rate is shown in FIG. 10. In the figure, the rhombus represents the release rate of estradiol and the square represents the release rate of compound 1. It can be seen that the target release rate has been achieved.
    [185] Experimental Example 3
    [186] Inserts according to Experimental Example 1 were prepared using gestodene and estradiol as active agents.
    [187] The insert structure was that disclosed in FIG. The first part of the nucleus consisted of PDMS containing Gestodene and was 13 mm long. The second part of the nucleus consisted of PEO-PDMS with 50% PEO, contained estradiol and was 30 mm long.
    [188] The nuclear portion was surrounded by a membrane consisting of PDMS and methyltrifluoropropyl-methylvinyl siloxane in a 70:30 ratio. The thickness of the membrane was 0.23 mm and the outer diameter of the insert was 2.48 mm.
    [189] The measured release rate is shown in FIG. 11. In the figure, the rhombus indicates the release rate of gestodene and the square indicates the release rate of estradiol.
    [190] Experimental Example 4
    [191] Inserts according to Experimental Example 1 were prepared using 7α-methyl-19-nortestosterone (MENT) and gestodene as activators.
    [192] The structure of the insert was that shown in FIG. The first portion of the nucleus consisted of Pt-catalyzed PDMS comprising 60 weight-% MENT and was 44 mm long by 3.0 mm in diameter. The second portion of the nucleus consisted of peroxide-catalyzed PDMS comprising 50 wt-% gestodene and was 12 mm long by 3.0 mm in diameter.
    [193] Both nuclear sections were wrapped in a membrane consisting of a mixture of PDMS and trifluoropropyl modified PDMS. The fluoro-content of the membrane varied from 55% to 75% by weight. The thickness of the membrane was 0.25 or 0.35 mm and therefore the outer diameter of the insert was 3.5 or 3.7 mm, respectively.
    [194] The measured release rates are shown in Figures 12-14. FIG. 12 shows the release rate of MENT and gestodene specified from the implant where the fluoro-content of the membrane is 55 wt-% and the thickness of the membrane is 0.25 mm. MENT is shown as a triangle and Gestöden is shown as a rhombus. It can be seen that the release rates of the two active agents are actually constant over time. Figures 13 and 14 show the release rate of MENT and gestodene on the action of the fluoro-content (55-75 wt-%), the thickness of the membrane (0.25 or 0.35 mm), respectively. It can be seen that by properly selecting the fluoro-content and thickness the release rate can be controlled with great precision. For example, in FIG. 14, the release rate of gestoden in the insert surrounded by a membrane having a fluoro-content of 60 wt-% and a thickness of 0.25 mm (indicated by a triangle) is fluoro-content of 60 wt-%, thickness of 0.35. greater than the release rate of the insert surrounded by the membrane with mm (represented by a square).
    权利要求:
    Claims (29)
    [1" claim-type="Currently amended] A nucleus and a membrane surrounding the nucleus, wherein the nucleus and the membrane consist essentially of the same or different elastomeric compositions, the nucleus comprising two or more therapeutically active agents having respective release rates.
    [2" claim-type="Currently amended] The delivery system of claim 1, wherein said nucleus consists of one portion comprising said two or more therapeutically active agents.
    [3" claim-type="Currently amended] The delivery system of claim 1, wherein the nucleus consists of at least first and second portions, each portion comprising one or more of the two or more therapeutically active agents.
    [4" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the first and second (and more) portions are adjacent to each other.
    [5" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the second (or more) portion at least partially surrounds the first (or second or more) portion.
    [6" claim-type="Currently amended] The delivery system of claim 1, wherein the membrane consists of two or more layers.
    [7" claim-type="Currently amended] The delivery system of claim 6, wherein the thickness of the layers is different.
    [8" claim-type="Currently amended] 4. The delivery system of claim 3, further comprising a space separating at least two portions of the nucleus into at least two.
    [9" claim-type="Currently amended] 4. The delivery system of claim 3 further comprising at least one separator separating at least two portions of said nucleus into at least two, said separator being essentially an elastomeric composition.
    [10" claim-type="Currently amended] The delivery system of claim 9, wherein the one or more separators are permeable to one or more therapeutically active agents.
    [11" claim-type="Currently amended] The delivery system of claim 9, wherein the one or more separators are impermeable to a therapeutically active agent.
    [12" claim-type="Currently amended] 10. A delivery system according to any one of claims 1 to 9, wherein said elastomeric composition is selected from the same or different and configured as follows.
    Elastomer compositions comprising poly (dimethylsiloxane),
    An elastomer composition comprising a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units,
    Elastomer compositions comprising poly (alkene oxide) groups, wherein the poly (alkene oxide) groups are present as alkoxy-terminated grafts or blocks linked to the polysiloxane units by silicon-carbon bonds, or as mixtures thereof, And
    Combinations of two or more thereof.
    [13" claim-type="Currently amended] 13. The delivery system of claim 12, wherein the substituent attached to the Si-atom of 1 to about 50% siloxane units in the siloxane-based elastomer is a 3,3,3-trifluoropropyl group.
    [14" claim-type="Currently amended] 13. The delivery system of claim 12, wherein the poly (alkene oxide) group is poly (ethylene oxide).
    [15" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the elastomeric compositions of two or more portions of the nucleus are identical.
    [16" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the elastomeric composition of two or more portions of the nucleus is different.
    [17" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the two or more portions of the membrane elastomeric composition are identical.
    [18" claim-type="Currently amended] 4. The delivery system of claim 3, wherein the two or more portions of the membrane elastomeric composition are different.
    [19" claim-type="Currently amended] The delivery system of claim 6, wherein the other layer elastomeric composition of the membrane is the same.
    [20" claim-type="Currently amended] The delivery system of claim 6, wherein the other layer elastomeric composition of the membrane is different.
    [21" claim-type="Currently amended] 10. The delivery system of claim 9, wherein the separator elastomer composition is the same.
    [22" claim-type="Currently amended] 10. The delivery system of claim 9, wherein the membrane elastomer composition is different.
    [23" claim-type="Currently amended] The delivery system of claim 1, wherein the release rates of the two or more therapeutically active agents are the same.
    [24" claim-type="Currently amended] The delivery system of claim 1, wherein the release rate of the two or more therapeutically active agents is different.
    [25" claim-type="Currently amended] The delivery system of claim 1, wherein the release rate is determined by the nucleus and the membrane.
    [26" claim-type="Currently amended] The delivery system of claim 1, wherein the release rate is determined by the membrane.
    [27" claim-type="Currently amended] The delivery system of claim 1, wherein the delivery system is an insert.
    [28" claim-type="Currently amended] The delivery system of claim 1, which is an intrauterine system, a cervical system or an intravaginal system.
    [29" claim-type="Currently amended] The delivery system of claim 1, wherein the therapeutically active agent is a hormone.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6068324B2|2017-01-25|Transdermal system, production method, and stabilization of amorphous drug
    US8968767B2|2015-03-03|Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
    US9775817B2|2017-10-03|Transdermal contraceptive hormones delivery
    US4906169A|1990-03-06|Transdermal estrogen/progestin dosage unit, system and process
    US6586000B2|2003-07-01|Hydroxide-releasing agents as skin permeation enhancers
    US4769028A|1988-09-06|Pharmaceutical product, in medical bandage form
    TWI277418B|2007-04-01|Enhanced drug delivery in transdermal systems
    FI110994B|2003-05-15|A pressure-sensitive binder composition for use in a transdermal drug delivery system and a process for making a transdermal drug delivery system containing a pressure-sensitive binder
    US6010716A|2000-01-04|Pharmaceutical composition for transdermal administration
    US10653619B2|2020-05-19|Drug depots for treatment of pain and inflammation
    US5660848A|1997-08-26|Subdermally implantable device
    AU674758B2|1997-01-09|Intravaginal delivery system
    FI119414B|2008-11-14|Intra-vaginal drug delivery devices for administration of oestradiol 17beta precursors
    US20170367876A1|2017-12-28|Intrauterine system
    EP0876815B1|2002-01-09|"Drug delivery system for two or more active substances"
    DE3131610C2|1991-10-02|
    EP1620060B1|2010-03-24|Methods and devices for the sustained release of multiple drugs
    US6835392B2|2004-12-28|Dual enhancer composition for topical and transdermal drug delivery
    EP0328524B1|1993-11-18|Transdermal fertility control system and process
    CA2088778C|2001-08-14|Transdermal contraceptive formulations, methods and devices
    CN1198603C|2005-04-27|Spray on bandage and drug delivery system
    FI58871B|1981-01-30|Ceiling inerhaollande en siloxanelastomer
    EP1487267B1|2008-10-29|Patch for the release of volatile substances to environment
    ES2268707T3|2007-03-16|Potential compositions of skin permeation including glicerol monolaurate and lauryl acetate.
    CA2232635C|2002-09-17|Intravaginal rings with insertable drug-containing core
    同族专利:
    公开号 | 公开日
    PL367961A1|2005-03-07|
    HU0401438A2|2004-11-29|
    WO2003017971A1|2003-03-06|
    RU2302883C2|2007-07-20|
    AU2002313517B2|2007-09-06|
    PE20030316A1|2003-04-03|
    NO20041315L|2004-03-30|
    CA2457979A1|2003-03-06|
    CN1289064C|2006-12-13|
    EP1427390A1|2004-06-16|
    RU2004109575A|2005-08-20|
    AR036310A1|2004-08-25|
    US20040247674A1|2004-12-09|
    JP2005503389A|2005-02-03|
    HU0401438A3|2008-04-28|
    CN1549703A|2004-11-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-08-31|Priority to US31597201P
    2001-08-31|Priority to US60/315,972
    2002-08-27|Application filed by 쉐링 오와이
    2002-08-27|Priority to PCT/FI2002/000692
    2004-05-03|Publication of KR20040036928A
    优先权:
    申请号 | 申请日 | 专利标题
    US31597201P| true| 2001-08-31|2001-08-31|
    US60/315,972|2001-08-31|
    PCT/FI2002/000692|WO2003017971A1|2001-08-31|2002-08-27|Drug delivery system|
    [返回顶部]